Immune checkpoint inhibitors for refractory childhood cancers

Affiliations

Comment

Brigitte C Widemann. Lancet Oncol. 2020 Jan.

. 2020 Jan;21(1):14-15.

doi: 10.1016/S1470-2045(19)30777-6. Epub 2019 Nov 25.

¹ Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA. Electronic address: widemanb@mail.nih.gov.

No abstract available

Comment on

Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study.
Geoerger B, Zwaan CM, Marshall LV, Michon J, Bourdeaut F, Casanova M, Corradini N, Rossato G, Farid-Kapadia M, Shemesh CS, Hutchinson KE, Donaldson F, Liao M, Caron H, Trippett T. Geoerger B, et al. Lancet Oncol. 2020 Jan;21(1):134-144. doi: 10.1016/S1470-2045(19)30693-X. Epub 2019 Nov 25. Lancet Oncol. 2020. PMID: 31780255 Clinical Trial.